Cardiac resynchronisation therapy (CRT) is a validated treatment for heart failure (HF) patients in NYHA class III–IV despite optimal medical therapy. We aimed to assess the beneficial effects of CRT in patients with catecholamine-dependent overt HF (CDOHF).